Company intelligence / Profile preview

Anvyl Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Anvyl specializes in developing small-molecule drugs targeting serious neurologic and psychiatric disorders. Its lead asset, AVL-3288, is a first-in-class type I positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The compound has been investigated for cognitive impairment associated with schizophrenia and other CNS conditions. Clinical development has included at least one trial initiation, but current status appears preclinical or early clinical without recent published results.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

AVL-3288

Partnerships

CoMentis – joint venture "Alpharmagen" focused on alpha7 modulators for cognition-related indications including schizophrenia and Alzheimer's disease.

Beyond the preview

Go deeper on Anvyl Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anvyl Pharmaceuticals.

Explore the full profile